The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.
Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.
Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.
For More Details Please Visit @:
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-drugs-market
Further key findings from the report suggest:
• EU5 is projected to be the second largest market with more than 10.0% share in 2022, owing to increasing ovarian cancer incidence and approval of PARP inhibitors
• Key players in the industry are focusing on collaborations for development, broader product portfolios, and regional expansion in emerging markets to increase their market share
• Combination regimens and pipeline breakthroughs, specifically those including checkpoint inhibitors such as Roche’s Tecentriq and Pfizer’s Bavencio, are poised to be the upcoming milestones for ovarian cancer treatment
• PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market through the forecast period. Factors such as continued uptake of approved PARP inhibitors owing to their superior efficacy, long treatment duration, and considerable number of treatment opportunities in first-line advanced settings are likely to propel the growth of the drug class.
• Although angiogenesis inhibitors accounted for the majority of shares in the market in 2016, the drug class is expected to capture a marginal share in 2022 owing to increasing competition from PARP inhibitors and novel pipeline products
• Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical trials
• A greater understanding of tumor microenvironment is estimated to occur, which would further drive successful development of new patient-specific therapies through the forecast period
• Late-stage pipeline includes novel drugs such as ImmunoGen’s mirvetuximab soravtansine and Vascular Biogenics’ VBL-111.
Grand View Research has segmented the global ovarian cancer drugs market based on therapeutic class and region:
Ovarian Cancer Drugs Therapeutic Class Outlook (Revenue, USD Million, 2016-2022)
• PARP Inhibitors
• Angiogenesis Inhibitors
• PD-L1 Inhibitors
Ovarian Cancer Drugs Country Outlook (Revenue, USD Million, 2016-2022)
• U.S.
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• U.K.
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• France
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• Germany
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• Italy
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• Spain
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
• Japan
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors